Arkema announces a major investment project in the biosourced polyamide 11 chain in Asia
Arkema announces a major investment plan in its biosourced polyamide 11 chain with a view to significantly increasing its production capacities in Asia.
Over the next five years, the Group plans to invest some 300 million euros in building, in Asia, a world-scale plant dedicated to producing Rilsan® PA11 biosourced polyamide from castor oil. The new plant, which will produce both the amino 11 monomer and its polymer, Rilsan® PA11, should come on stream in late 2021. It will enable Arkema to increase by 50% its Rilsan® PA11 (powder and granule) production capacity. The investment also includes a 50% increase in global production capacities for Pebax®, in particular Pebax® RNew of which amino 11 is a key component. Pebax® RNew is a biosourced polyamide elastomer with unique properties such as energy return and flexibility, earmarked in particular for the sports and electronics markets.
With this upcoming plant, Arkema will have a second amino 11 monomer production site, complementing its historical site in Marseille, France.
Rilsan® PA11 is the only high performance 100% biosourced polyamide to qualify for the most exacting applications in particular in the electronics, 3D-printing and automotive markets, where it serves as a metal substitute.
This investment illustrates the Group’s long-term commitment to fulfil strong demand from its customers in Asia by offering biosourced solutions to the key challenges of lightweighting and design of materials. Over the next few years, annual growth of some 7% is forecast in these markets in Asia.
With this project, the specialty polyamides business, which already achieves 40% of its sales in Asia, will bolster its industrial, commercial and R&D presence in the region. The Group thereby confirms its commitment to support its customers by working closely on their individual needs and providing them with the right innovative solutions that match the local specifics of their various markets.
This project is consistent with the Group’s ambitious strategy to significantly step up the development of its advanced materials, which should eventually account for over 25% of sales, while continuing to further consolidate its presence in Asia.